Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009340 | Panoply™ Human MDM2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC009340 | Panoply™ Human MDM2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT0516 | Human MDM2 Knockout Cell Line-HeLa | Inquiry |
| CLKO-0021 | MDM2 KO Cell Lysate-HeLa | Inquiry |
| CSC-RT2718 | Human MDM2 Knockout Cell Line-HEK293T | Inquiry |
| CSC-RT2719 | Human MDM2 Knockout Cell Line - SK-OV-3 | Inquiry |
| CSC-RT2782 | Human MDM2 Knockout Cell Line-A549 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD00359Z | MDM2 adenovirus | Inquiry |
| AD09786Z | Human MDM2 adenoviral particles | Inquiry |
| LV18002L | human MDM2 (NM_002392) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH339679 | shRNA set against Mouse MDM2 (NM_010786.3) | Inquiry |
| SHW003207 | shRNA set against Chicken MDM2 (NM_001199384) | Inquiry |
| SHH339683 | shRNA set against Rat MDM2 (NM_001108099.1) | Inquiry |
| SHW014830 | shRNA set against Danio rerio MDM2 (NM_131364) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR007764 | Rat Mdm2 cDNA Clone(NM_001108099.1) | Inquiry |
| MiUTR1M-07025 | MDM2 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-03745 | MDM2 miRNA 3'UTR clone | Inquiry |
| SKO0007 | MDM2 Validated sgRNA vector | Inquiry |
| CDCB164682 | Chicken MDM2 ORF Clone (NM_001199384) | Inquiry |
| CDCB176305 | Danio rerio MDM2 ORF Clone (NM_131364) | Inquiry |
| CDCB193402 | Rabbit MDM2 ORF clone (XM_008256766.1) | Inquiry |
| CDCH30254Q | Human MDM2 ORF Clone(NM_002392.3) | Inquiry |
| CDCL185308 | Mouse MDM2 ORF clone(NM_010786.3) | Inquiry |
| CDCR374791 | Rat Mdm2 ORF Clone(NM_001108099.1) | Inquiry |
Murine double minute 2 (MDM2) is an important negative regulator of p53, regulating cell proliferation and apoptosis through p53 pathway and non-p53-dependent pathway. It plays an important role in the development of tumors. At present, MDM2 gene mutation, amplification and overexpression are confirmed in various human tumors, and the expression and dysfunction of this gene have different effects on the susceptibility, biological behavior, prognosis and treatment of malignant tumors.
Biological Function of MDM2
Numerous studies have shown that p53 protein is one of the most important molecules in human tumorigenesis. The tumor suppressor gene TP53 inhibits cell proliferation and promotes cell apoptosis by regulating cell cycle arrest during cell cycle arrest, apoptosis, and DNA repair. Its functional status affects tumorigenesis and development, so the prognosis and the relationship between this gene and tumor patients Chemotherapeutic drug sensitivity is related. Inactivation of p53 is implicated in most human tumors, including TP53 mutations, deletion of p53 positive regulators, inactivation, methylation of the p53 promoter, and overexpression of MDM2 and its family members.
Figure 1. Regulation of the Mdm2–p53 pathway by the ubiquitin E3 ligase MARCH7. (Zhao, et al. 2018)
As an important negative regulator of p53 function, MDM2 is an important component of p53 signaling pathway and plays an important role in the development of tumors. A variety of cellular stresses such as hypoxia, DNA damage, and oncogene activation simultaneously activate p53 and its downstream MDM2 gene. When TP53 gene activates cell cycle regulation, the level of p53 is down-regulated due to elevated MDM2 level, leading to the formation of a negative feedback regulatory loop, which precisely regulates intracellular p53 levels and regulates cell proliferation and apoptosis. MDM2 can regulate the function of p53 in several ways. MDM2 can directly bind to p53, block the interaction of p53 protein with related transcription factors, inhibit the transcription factor activity of p53, and thus inhibit the transcription of p53 downstream genes. MDM2 can also mediate the transfer of p53 protein binding from it to the cytoplasm. The E3 ubiquitinating enzyme activity of MDM2 enables ubiquitination of its associated p53 protein, which is then degraded by proteolytic enzymes.
MDM2 and Malignant Tumor
In recent years, in breast cancer, studies have shown that MDM2 SNP309 polymorphism is mostly related to race, especially in women in China, that is, women with SNP polymorphism have breast cancer than women without this polymorphism. The risk is great. In addition, immunohistochemistry was used to detect the expression of MDM2 in 90 invasive ductal tissues of breast and 30 normal tissues. The positive rate of expression in cancer tissues was 81. 1%, significantly higher than the positive rate of expression in normal tissues. 3%, its overexpression is associated with the presence or absence of axillary lymph node metastasis and pathological grade, indicating that this protein plays an important role in the occurrence, development and metastasis of invasive ductal carcinoma of the breast.
The expression of MDM2 in 70 cases of hepatocellular carcinoma and 40 cases of adjacent tissues was detected by immunohistochemical EliVision method. The results showed that the positive expression rate of MDM2 in hepatocellular carcinoma was significantly higher than that in adjacent tissues. The rate was statistically significant in the presence or absence of lymph node metastasis and tumor size. This suggests that abnormalities in the MDM2 gene may be a poor indicator of the prognosis of hepatocellular carcinoma. The expression level of MDM2 protein in laryngeal squamous cell carcinoma was detected by immunohistochemistry. The results showed that MDM2 was highly expressed in laryngeal carcinoma tissues, and the lower the degree of differentiation, the higher the positive expression rate.
References: